Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Dendritic Cell as Potential Immunotherapy for Nasopharyngeal Cancer: A Review

The Indonesian Biomedical Journal · Vol. 15 No. 5 (2023) · hlm. 269–277

DOI
10.18585/inabj.v15i5.2389
ISSN
2085-3297, 2355-9179
Terbit
2023-10-18
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Dendritic cell (DC)-based cancer therapy is a promising adjuvant therapy for nasopharyngeal cancer (NPC) after chemoradiation. Owing to low immunity after chemoradiation, DC therapy activates immune responses. Moreover, DC-based cancer therapy can decrease tumor progression, prolong lifespan, and increase the quality of life of patients. Various studies regarding the use of DC therapy for NPC have been reported, however there are limited reviews on the implementation and foundation of DC immunotherapy to expand this technology.METHODS: A literature search was performed on EMBASE, ScienceDirect, PubMed (MEDLINE), and Cochrane Library, with the term dendritic cells therapy for nasopharyngeal cancer, dendritic cell immunotherapy in nasopharyngeal cancer patients, and DC therapy in NPC, as the search keywords.RESULTS: A total of 199 literatures were reviewed, and four clinical trials were identified as relevant for this review. DC vaccines can be processed with various maturation and activation processes. Selected literatures reported antigens used when incubating the DC are latent membrane protein (LMP) 1, LMP2, and Epstein–Barr virus nuclear antigen 1 (EBNA1). Although DC therapy was produced from different pathways, it has been reported that there are increases of cluster of differentiation (CD)8+ T cells, CD4+ T cells, and the progression free survival (PFS) rate in DC immunotherapy patients than the radiochemotherapy patients.CONCLUSION: It can be concluded that DC could be used as an adjuvant therapy alongside the standard therapy of NPC, which prolongs NPC patient survival.KEYWORDS: adjuvant cell therapy, nasopharyngeal cancer therapy, dendritic cells

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 152 tautan kepenulisan bersama · 79 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Hasanuddin University
  • Padjadjaran University
  • PT Prodia StemCell Indonesia (Indonesia)
  • Udayana University
  • University of Indonesia
  • Universitas Trisakti
  • Universitas Airlangga
  • Organisasi lain
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Anna MeilianaPadjadjaran University88
Nurrani Mustika DewiPadjadjaran University45
Suryani As’ádHasanuddin University14
Nisa ZulfaniPT Prodia StemCell Indonesia (Indonesia)8
Yani LinaHasanuddin University6
Gatot Susilo LawrenceHasanuddin University6
Ahmad FariedPadjadjaran University6
Keri LestariPadjadjaran University6
Keri LestariPadjadjaran University5
Cecilia Aileen YapPT Prodia StemCell Indonesia (Indonesia)5
Ilhamjaya PatellongiHasanuddin University4
Anwar SantosoUdayana University4
Syakib BakriHasanuddin University4
Teguh RanakusumaUniversity of Indonesia3
Irawan YusufHasanuddin University3
Trilis YuliantiHasanuddin University3
Melisa Intan BarlianaPadjadjaran University3
Bayu Winata PuteraHasanuddin University3
Yenny SurjawanHasanuddin University2
Irma Ruslina DefiPadjadjaran University2
Mansyur AriefHasanuddin University2
Andri HidayatHasanuddin University2
Ferry SandraUniversitas Trisakti2
Marsetio DonosepoetroUniversitas Airlangga2
Burhanuddin BaharHasanuddin University2
Lucia HerminawatiHasanuddin University2
Widjaja LukitoSEAMEO Regional Center for Food and Nutrition2
Indriyanti Rafi SukmawatiHasanuddin University2
Antonia Anna LukitoHasanuddin University2
Mansyur ArifHasanuddin University2
Angliana ChouwPT Prodia StemCell Indonesia (Indonesia)2

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Dendritic Cell as Potential Immunotherapy for Nasopharyngeal Cancer: A Review</dc:title><dc:creator>Albertus Budi Sulistya</dc:creator><dc:creator>Rima Haifa</dc:creator><dc:creator>Geofanny Facicilia</dc:creator><dc:creator>Kristin Talia Marbun</dc:creator><dc:creator>Marsya Nilam Kirana</dc:creator><dc:creator>Yussy Afriani Dewi</dc:creator><dc:creator>Cynthia Retna Sartika</dc:creator><dc:creator>Andi Wijaya</dc:creator><dc:creator>Keri Lestari Dandan</dc:creator><dc:subject>dendritic cell immunotherapy</dc:subject><dc:subject>nasopharyngeal carcinoma</dc:subject><dc:subject>dendritic cell vaccine</dc:subject><dc:subject>adjuvant therapy</dc:subject><dc:subject>chemoradiotherapy</dc:subject><dc:subject>Epstein-Barr virus</dc:subject><dc:subject>latent membrane protein 1</dc:subject><dc:subject>latent membrane protein 2</dc:subject><dc:subject>EBNA1</dc:subject><dc:subject>CD8+ T cells</dc:subject><dc:subject>CD4+ T cells</dc:subject><dc:subject>progression-free survival</dc:subject><dc:description xml:lang="en">BACKGROUND: Dendritic cell (DC)-based cancer therapy is a promising adjuvant therapy for nasopharyngeal cancer (NPC) after chemoradiation. Owing to low immunity after chemoradiation, DC therapy activates immune responses. Moreover, DC-based cancer therapy can decrease tumor progression, prolong lifespan, and increase the quality of life of patients. Various studies regarding the use of DC therapy for NPC have been reported, however there are limited reviews on the implementation and foundation of DC immunotherapy to expand this technology.METHODS: A literature search was performed on EMBASE, ScienceDirect, PubMed (MEDLINE), and Cochrane Library, with the term dendritic cells therapy for nasopharyngeal cancer, dendritic cell immunotherapy in nasopharyngeal cancer patients, and DC therapy in NPC, as the search keywords.RESULTS: A total of 199 literatures were reviewed, and four clinical trials were identified as relevant for this review. DC vaccines can be processed with various maturation and activation processes. Selected literatures reported antigens used when incubating the DC are latent membrane protein (LMP) 1, LMP2, and Epstein–Barr virus nuclear antigen 1 (EBNA1). Although DC therapy was produced from different pathways, it has been reported that there are increases of cluster of differentiation (CD)8+ T cells, CD4+ T cells, and the progression free survival (PFS) rate in DC immunotherapy patients than the radiochemotherapy patients.CONCLUSION: It can be concluded that DC could be used as an adjuvant therapy alongside the standard therapy of NPC, which prolongs NPC patient survival.KEYWORDS: adjuvant cell therapy, nasopharyngeal cancer therapy, dendritic cells</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2023-10-18</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>http://dx.doi.org/10.18585/inabj.v15i5.2389</dc:identifier><dc:identifier>10.18585/inabj.v15i5.2389</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 15 No 5 (2023); 269-277</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/2389/661</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>